openPR Logo
Press release

PD-1 and PDL-1 Inhibitors Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

09-04-2018 01:20 PM CET | Health & Medicine

Press release from: CMI - Pharmaceutical Industry

PD-1 and PDL-1 Inhibitors Market

PD-1 and PDL-1 Inhibitors Market

Targeted cancer therapy is the primary objective of extensive research related to cancer drugs. Our immune cells are programmed to attack the foreign cell on activation. PD-1 and PDL-1 are among those activation points present on the immune cells. Sometimes cancer cells also use this PD-1 and PDL-1 trigger points to avoid being attacked by the immune cells. Therefore, cancer drugs targeting these cells hold tremendous potential in the cancer treatment market. Approved PD-1 and PDL-1 inhibitor drugs have become blockbuster products.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/173

PD-1 inhibitors are effective in treating non-small-cell lung carcinoma (NSCLC), kidney cancer, melanoma of the skin, head and neck cancers, bladder cancer, and Hodgkin lymphoma. Opdivo is leading the race with US$ 3.8 Bn in sales in 2016, compared to US$ 1.4 Bn of Keytruda in 2016. Both these drugs have garnered significant development in past two years with respect to extended therapeutic application and approvals in European countries and Japan.

PDL-1 inhibitors are proven to be effective in NSCLC, bladder cancer, and Merkel cell skin cancer. Avelumab received FDA approval in March 2017 for metastatic Merkel cell carcinoma (MCC), a rare skin cancer with no approved therapies. The drug therefore, received approval under the accelerated approval process, requiring the developers, Pfizer, Inc. and Merck KGaA to conduct larger clinical trials to establish complete safety and efficacy of the drug. The drug is also being tested for bladder cancer, NSCLC, gastric cancer, ovarian cancer, and renal cancer, under the JAVELIN clinical trial program. Extended therapeutic applications widens the potential opportunity for the drugs in the global PD-1 inhibitors and PDL-1 inhibitors market.

Download PDF Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-pdf/173

Key Vendors of PD-1 and PDL-1 Inhibitors Market: Pfizer, Inc., Bristol-Myers Squibb, Merck KGaA, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, and Ono Pharmaceutical Co., Ltd.

The global PD-1 and PDL-1 inhibitors market is segmented based on the drug type and application as follows:

Drug Type

PD-1 inhibitors
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
PDL-1 inhibitors
- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)

Applications
Non-small cell lung cancer
Kidney cancer
Melanoma of the skin
Bladder cancer
Merkel cell skin cancer
Others

Ask for TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/173

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release PD-1 and PDL-1 Inhibitors Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 here

News-ID: 1219010 • Views:

More Releases from CMI - Pharmaceutical Industry

Empty Capsules Market to Surpass US$ 2.79 Billion Threshold by 2025 Globally | Leading Players ACG Associated Capsules Pvt. Ltd., Capsugel, Inc., CapsCanada Corporation, Medicaps Ltd., Qualicaps, Inc., JC Biological Technology Co., Patheon, Inc., Roxlor L
Empty Capsules Market to Surpass US$ 2.79 Billion Threshold by 2025 Globally | L …
The Global Empty Capsules Market by Product Type (Gelatin Capsules (Porcine, Bovine, and Bone Meal), Non-Gelatin Capsules (HPMC and Pullulan)), By Application (Antibiotics, Vitamins, Anti-Inflammatory, Anti-Anemic and Others), By End User (Pharmaceutical Manufacturers, Nutraceutical Manufacturers and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 1.55 billion in 2016 and is projected to exhibit a CAGR of 7.7% over the
Significant Number of Pipeline Drugs to Surge Hereditary Angioedema Market beyond US$ 3.4 Billion by 2025 | Top Players CSL Behring, Shire Plc., Pharming Healthcare, Inc., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Arrowhead Pharmaceutic
Significant Number of Pipeline Drugs to Surge Hereditary Angioedema Market beyon …
The Global Hereditary Angioedema Market, by Drug Class (C1 Esterase Inhibitor, Kallikrein Inhibitor, Bradykinin Receptor, Attenuated Androgens, and Others), by Route of Administration (Subcutaneous, Intravenous, and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 1,563.7 million in 2016 and is projected to exhibit a CAGR of 9.1% over the
Ulcerative Colitis Market to Incur Fortitude Growth During 2018-2026 by Global Top Players - AbbVie Inc., Hospira, Celltrion Healthcare, Johnson and Johnson, F. Hoffmann-La Roche AG, Warner Chilcott, Janssen Pharmaceuticals Inc. and Takeda Pharmaceuticals
Ulcerative Colitis Market to Incur Fortitude Growth During 2018-2026 by Global T …
Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. These disease can affect people of any age, though prevalence is especially high among people under 30 years of age. The major symptoms of this disease are diarrhea, belly pain/cramps, bleeding from the rectum, also other indications are sudden and unexplained
Dermal Regeneration Template Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Dermal Regeneration Template Market - Global Industry Insights, Trends, Outlook, …
Dermal regeneration template is a two-layered skin regeneration system. The outer layer of dermal regeneration template is made of thin silicone film act as the epidermis of skin. The outer layer of dermal regeneration template helps in protecting wound from infection and controls in loss of both heat and moisture. The outer collagen Glycosaminoglycan (GAG) thermal layer functions as a biodegradable template that helps in regeneration of dermal tissue neodermis

All 5 Releases


More Releases for Inhibitors

Thymidine Phosphorylase Inhibitors Market - Breaking the Cycle: Angiogenesis Inh …
Newark, New Castle, USA: The "Thymidine Phosphorylase Inhibitors Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Thymidine Phosphorylase Inhibitors Market: https://www.growthplusreports.com/report/thymidine-phosphorylase-inhibitors-market/8826 This latest report researches the industry structure,
CGRP Inhibitors Market - Break Free from Migraine: CGRP Inhibitors Redefining Re …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global CGRP Inhibitors Market. CGRP Inhibitors Market: https://www.growthplusreports.com/report/cgrp-inhibitors-market/9155 The CGRP Inhibitors Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy.
Proton Pump Inhibitors Market - Silencing Acid, Empowering Relief: Proton Pump I …
Newark, New Castle, USA: The "Proton Pump Inhibitors Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Proton Pump Inhibitors Market: https://www.growthplusreports.com/report/proton-pump-inhibitors-market/8415 This latest report researches the industry structure,
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts
Crude Oil Flow Improvers Market by Type (Paraffin Inhibitors, Asphaltene Inhibit …
Global Crude Oil Flow Improvers Market was valued at $1,282 million in 2016, and is anticipated to reach $1,920 million, growing at a CAGR of 5.7% from 2017 to 2023. Crude oil is one of the most actively traded commodities with a stable growth rate globally. It is extracted from remote locations and needs to be transported through pipelines. Transportation of crude oil via pipeline is relatively difficult, owing to
Immune Check Point Inhibitors Market Immune Check Point Inhibitors Clinical Pipe …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Immune Checkpoint Inhibitors- Introduction to Next Generation Cancer Immunotherapy 1.1 Overview 1.2 History- From Tragedy to Breakthrough Major Immune Checkpoints Proteins 2.1 Role of Cytotoxic T lymphocyte Antigen-4 (CTLA-4) in Cancer Development 2.2 Role of Programed Cell Death Protein 1 (PD1) in Cancer Development Mechanism of Action of Immune Checkpoint Inhibitors 3.1 Cytotoxic T lymphocyte Antigen-4